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ABSTRACT 
In this post hoc analysis of the randomized controlled LixiLan-O trial in insulin-naive type 2 
diabetes mellitus (T2DM) patients not controlled on metformin with or without a second oral 
antihyperglycaemic drug (OAD), the efficacy and safety of the fixed-ratio combination, iGlarLixi 
(insulin glargine 100 U [iGlar] and lixisenatide [Lixi]), compared to its individual components was 
assessed in two patient subgroups: (1) a baseline HbA1c ≥9% (n = 134); (2) inadequate control 
(HbA1c ≥7.0% and ≤9.0%) despite administration of two OADs at screening (n = 725). 
 Treatment with iGlarLixi resulted in a significantly greater reduction in least squares mean 
HbA1c compared with iGlar or Lixi alone in both subgroups (HbA1c ≥9% group: 2.9%, 2.5%, 
1.7%; two OADs group: 1.5%, 1.2%, 0.7%, respectively). Target HbA1c <7% was achieved in 
>70% of patients on iGlarLixi in both subgroups, while mitigating the weight gain observed with 
iGlar alone. Rates of hypoglycaemic events were low overall. 
 These results suggest that iGlarLixi achieves superior glycaemic control compared with 
iGlar or Lixi alone in T2DM patients with HbA1c ≥9% or those inadequately controlled on two 
OADs. 
 
Trial registration number: NCT02058147 (LixiLan-O) 
 
Keywords (3–10 keywords required): 
glycaemic control, iGlarLixi, insulin glargine 100 U, lixisenatide, type 2 diabetes mellitus 
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1  |  INTRODUCTION 
The 2018 American Diabetes Association(ADA)/European Association for the Study of Diabetes 
(EASD) consensus report on the management of hyperglycaemia in type 2 diabetes mellitus 
(T2DM) recommend that glycaemic targets should be individualized based on patient 
preferences and goals and the risk of adverse treatment effects, and that combination therapy 
may be considered in patients presenting with glycated haemoglobin (HbA1c) levels >1.5% 
above their target.1 In addition, in patients with an HbA1c >2% above target or >10%, 
recommendations include combination therapy with both basal insulin and a glucagon-like 
peptide-1 receptor agonist (GLP-1 RA) (or a fixed-ratio combination thereof) or a basal–prandial 
combination.1 This consensus report is aligned with the UK National Institute for Health and 
Care Excellence diabetes management guidelines, which also recommends considering fixed 
mixed insulin combinations (premixed insulins).2 For patients uncontrolled on two oral 
antihyperglycaemic drugs (OADs), both reports recommend treatment intensification with a third 
OAD, insulin initiation or a GLP-1 RA.1-3 
 In spite of current recommendations, treatment of diabetes worldwide remains suboptimal, 
with many patients failing to achieve targets despite the approval of over 40 new treatment 
options worldwide since 2005.4-8 While reasons for suboptimal glycaemic control are multiple, 
major contributing factors include, non-adherence to treatment, therapeutic inertia, and resource 
limitations.1,6,8,9 Adverse events, including hypoglycaemia, and weight gain may also affect 
patient adherence and healthcare professionals’ confidence in therapy.1,6,8,9 Moreover, 
employing a stepwise approach to treatment intensification may prolong the time to reach 
effective treatment(s)10 and possibly contributes to treatment non-adherence. Treatment 
approaches that simplify therapy and accelerate time to reach target HbA1c, such as early 
treatment with a fixed-ratio combination of basal insulin and a GLP-1 RA,1,10,11 could help to 
address therapeutic inertia, improve outcomes and prevent complications. 
 The once-daily, titratable, fixed-ratio combination of basal insulin glargine 100 U (iGlar) and 
the GLP-1 RA lixisenatide (Lixi), iGlarLixi, allows for a single, daily injection targeting both 
fasting and postprandial glucose. The LixiLan-O trial (NCT02058147) enrolled 1170 patients 
with T2DM inadequately controlled on metformin with or without a second OAD and found 
greater HbA1c reductions at Week 30 with iGlarLixi versus iGlar or Lixi alone with no increased 
risk of hypoglycaemia versus iGlar.12 iGlarLixi also mitigated the weight gain observed with iGlar 
alone.  
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 In this post hoc, subgroup analysis of patients from the LixiLan-O trial, we assessed 
whether intensification to iGlarLixi was efficacious in achieving glycaemic targets in patients with 
HbA1c ≥9% and those with inadequate glycaemic control (HbA1c ≥7.0% and ≤9.0%) on two 
OADs. These subgroups of patients were selected because they are predicted to be more 
difficult to treat with a lower likelihood of reaching target HbA1c. These are also patients who, 
current guidelines recognise, may need an injectable combination therapy to rapidly achieve 
glycaemic control, or represent a patient population for whom treatment with two OADs is 
insufficient. 
 
2  |  METHODS  
2.1  |  LixiLan-O study  
The LixiLan-O study design and main results have been published previously.12 Briefly, LixiLan-
O was a 30-week, open-label, randomized, multicentre, Phase 3 clinical trial, enrolling insulin-
naive T2DM patients, aged ≥18 years, with inadequate glycaemic control despite being treated 
for at least 3 months with metformin with or without a second OAD.  Inadequate glycaemic 
control was defined as HbA1c ≥7.5% and ≤10.0% for patients treated with metformin alone and 
≥7.0% and ≤ 9.0% for those treated with metformin and a second OAD. Eligible patients entered 
a 4-week run-in phase during which all OADs except metformin were stopped. In the current 
post hoc study the efficacy and safety of iGlarLixi compared to its individual components was 
assessed in two patient subgroups: (1) those with a baseline (after run-in) HbA1c ≥9%; (2) 
those with inadequate control (HbA1c ≥7.0% and ≤9.0%) despite administration of two OADs at 
screening. The study was designed and monitored in accordance with Good Clinical Practice, 
the International Conference on Harmonisation, and the Declaration of Helsinki. Institutional 
review boards or ethics committees at each study site approved the protocol. Each patient gave 
written informed consent. This manuscript was prepared in line with the Consolidated Standards 
of Reporting Trials guidelines. 
 
2.2  |  Interventions 
At the end of run-in, patients were randomized (2:2:1) to receive iGlarLixi, iGlar or Lixi. iGlarLixi 
was self-administered once daily, in the hour (0–60 minutes) before breakfast, by SoloSTAR® 
(Sanofi; Paris, France) pen; doses ranged from 10 U/5 μg to 60 U/20 μg of iGlar/Lixi, 
respectively. iGlar was self-administered once daily, at any time of the day but at about the 
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same time every day, by disposable prefilled Lantus SoloSTAR® (Sanofi) pen (100 U/mL) with 
doses starting at 10 U and capped at 60 U. Lixi was self-administered once daily, in the hour (0–
60 minutes) before breakfast, (10 μg for 2 weeks and up-titrated to 20 μg maintenance dose) by 
disposable prefilled pens (Sanofi). The same dose adjustment algorithm was recommended for 
iGlar and iGlarLixi. After the first week, the dose was titrated once a week based on insulin 
glargine dose until the patient reached a target fasting self-monitored plasma glucose of 80–100 
mg/dL without hypoglycaemia episodes. 
 
2.3  |  Post hoc analysis 
Efficacy outcomes in the two subgroups included the effect of treatment on HbA1c and body 
weight, and final iGlar and Lixi doses. Safety outcomes in these subgroup analyses included 
gastrointestinal treatment-emergent adverse events (TEAEs). In addition, the proportion of 
patients with clinically important hypoglycaemia (accompanied by plasma glucose <54 mg/dL) 
was assessed. Severe symptomatic hypoglycaemia was defined as requiring another person’s 
assistance actively to administer carbohydrate, glucagon, or other resuscitative actions. 
 
2.4  |  Statistical analyses 
Differences between treatments were determined using an analysis of covariance model with 
treatment groups, randomization strata of HbA1c at screening (<8%, ≥8%), and country as fixed 
effects, and baseline value as a covariate, unless otherwise stated. Differences in proportion 
were analysed using the Cochran–Mantel–Haenszel method. Safety analysis was performed 
descriptively. 
 The analysis populations were the modified intent-to-treat (mITT) population, comprising all 
randomized patients with a baseline and at least one post-baseline assessment, and the safety 
population, comprising all randomized patients who received at least one dose of study drug. 
 
3  |  RESULTS 
3.1  |  Patient disposition and demographics 
At the end of the run-in period, 6% (71 out of 1167) of the patients randomized in LixiLan-O 
were on two OADs at screening and also had an HbA1c ≥9% at baseline (after run-in). These 
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patients were therefore included in both subgroup analyses. The two subgroup analyses 
included 134 patients with baseline HbA1c ≥9% (subgroup 1) and 725 patients receiving two 
OADs at screening (subgroup 2; mITT populations contained 133 and 722 patients, 
respectively). Demographics and baseline characteristics were well balanced across treatment 
groups within each subgroup and generally similar to the overall study cohort (Table S1). 
 
3.2  |  Efficacy outcomes 
In line with the overall cohort, treatment with iGlarLixi achieved statistically significant greater 
improvements in HbA1c at Week 30 compared with iGlar or Lixi alone in both subgroups (Figure 
1). 
 
3.2.1  |  Patients with HbA1c ≥9% at baseline 
Treatment with iGlarLixi, iGlar and Lixi reduced least squares (LS) mean HbA1c by 2.9%, 2.5% 
and 1.7%, respectively (P = 0.0297 for iGlarLixi versus iGlar; P < 0.0001 for iGlarLixi versus Lixi; 
final mean HbA1c at Week 30: 6.8%, 7.3% and 8.1%, respectively; Figure 1a). Furthermore, 
73.5% of patients achieved HbA1c levels <7% by Week 30 with iGlarLixi versus 47.3% with 
iGlar and no patients with Lixi (Figure 1b). 
 Patients on iGlarLixi tended to gain less weight compared with iGlar (LS mean weight gain: 
1.3 kg versus 2.0 kg; P = 0.3; Figure 1c). 
 
3.2.2  |  Patients with two OADs at screening 
Treatment with iGlarLixi, iGlar and Lixi reduced LS mean HbA1c by 1.5%, 1.2% and 0.7%, 
respectively (P < 0.0001 for both iGlarLixi versus iGlar and iGlarLixi versus Lixi), from a mean 
baseline value of 8.0%, 8.0% and 8.1%, respectively (final mean HbA1c at Week 30: 6.6%, 
6.9% and 7.4%, respectively; Figure 1a). Moreover, 72.4% of patients achieved HbA1c levels 
<7% by Week 30 with iGlarLixi versus 57.8% with iGlar and 27.6% with Lixi (Figure 1b). 
Treatment with iGlarLixi resulted in significantly less weight gain than with iGlar (LS mean 
weight change: –0.1 versus +1.3 kg; P < 0.0001; Figure 1c). 
 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
 8 
3.3  |  Final iGlar and Lixi doses 
In the overall study population and both subgroups, final iGlar doses were similar in iGlarLixi 
and iGlar treatment groups (40–45 U; Table S2). For iGlarLixi, final mean doses of the Lixi 
component were similar (16–17 μg) in the overall study cohort and both subgroups (Table S2). 
 
3.4  |  Safety outcomes 
Consistent with the entire LixiLan-O population, gastrointestinal TEAE rates in the iGlarLixi arm 
were lower compared with the Lixi arm, and higher compared with the iGlar arm in both 
subgroups. The rates of gastrointestinal TEAEs leading to discontinuation were low in both 
subgroups (Table 1).  
 Rates of clinically important hypoglycaemia were similar for the iGlarLixi and iGlar arms in 
the overall population and the two OADs subgroup (Table 1), but numerically higher in the 
iGlarLixi versus iGlar arm in the HbA1c ≥9% subgroup. As the number of patients with 
hypoglycaemic events was low, no meaningful statistical testing could be performed. One 
patient in the iGlar arm in the two OADs subgroup experienced severe symptomatic 
hypoglycaemia.  
 
4  |  CONCLUSIONS 
In these post hoc analyses of insulin-naive patients with T2DM on metformin with an HbA1c 
≥9% or inadequately controlled on two OADs at screening, treatment with iGlarLixi resulted in a 
greater reduction in HbA1c compared with iGlar or Lixi alone. In both subgroups, over 70% of 
patients treated with iGlarLixi achieved an HbA1c <7%. Consequently, the fixed-ratio 
combination of iGlar and Lixi, delivered via a single daily injection in iGlarLixi, with its 
complementary mechanism of action targeting both fasting and postprandial hyperglycaemia, is 
a viable treatment option for patients with T2DM who have HbA1c levels ≥9% or failed to 
achieve glycaemic control on two OADs.   
 There are some limitations to this post hoc analysis. The original trial was not designed or 
powered to detect differences between treatments within these two subgroups. Additionally, the 
LixiLan-O study did not apply forced titration but allowed the investigator to make clinical 
judgements on dosing while avoiding hypoglycaemic episodes. Despite reaching a similar 
fasting plasma glucose at the end of the study,12 with a similar unit of insulin glargine 
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(Supplementary Table 2) and a similar titration algorithm, a greater proportion of patients treated 
with iGlarLixi achieved the HbA1c target compared with those treated with iGlar. In both arms, 
there was a proportion of patients who did not reach HbA1c <7% and may have benefitted from 
further up-titration. Finally, sample sizes, particularly for the HbA1c ≥9% subgroup, were rather 
small. Patient populations with HbA1c ≥9% are often not well represented in randomized clinical 
trials, and data focusing on this group are limited. The findings presented here would benefit 
from validation in a prospective, randomized trial in a larger patient cohort or in a real-world 
setting. 
 The results of these subgroup analyses, within the context of the limitations of a post hoc 
analysis, are in line with the recent ADA/EASD consensus statement1 and NICE guidelines2 
recommending the initiation of a combination of basal insulin and a GLP-1 RA in patients with 
an HbA1c >2% above target or >10% overall. The achievement of HbA1c <7% by >70% of 
patients via a single therapeutic intervention may facilitate treatment intensification in this 
difficult-to-treat patient group.  
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FIGURE 1 HbA1c and body weight outcomes for patients with T2DM from the overall 
LixiLan-O study population,12 patients with baseline HbA1c ≥9% and patients with two OADs 
according to randomization strata at screening (mITT population). 
Error bars indicate SE. 
Abbreviations: ANCOVA, analysis of covariance; BL, baseline; CI, confidence interval; 
HbA1c, glycated haemoglobin; iGlar, insulin glargine 100 U; iGlarLixi, insulin glargine and 
lixisenatide; Lixi, lixisenatide; LOCF, last observation carried forward; LS, least squares; 
mITT, modified intent-to-treat; MMRM, mixed-effect model with repeated measures; OAD, 
oral antihyperglycaemic drug; SD, standard deviation; SE, standard error; T2DM, type 2 
diabetes mellitus. 
†Overall LixiLan-O data based on MMRM analysis.  
‡LS mean difference for iGlarLixi versus iGlar or lixisenatide alone, ANCOVA; LOCF was 
used to handle missing data. 
§Differences in the proportions of patients achieving HbA1c <7% were analysed based on 
weighted average differences between treatment groups from each strata using a Cochran–
Mantel–Haenszel method. 
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TABLE 1 Clinically important hypoglycaemia outcomes and gastrointestinal disorders (safety population) 
 All patients 
(N = 1169) 
Patients with baseline HbA1c ≥9%  
(n = 134) 
Patients with two OADs according to 
randomization strata at screening  
(n = 724) 
 iGlarLixi 
(n = 469) 
iGlar 
(n = 467) 
Lixi 
(n = 233) 
iGlarLixi 
(n = 50) 
iGlar 
(n = 55) 
Lixi 
(n = 29) 
iGlarLixi 
(n = 291) 
iGlar 
(n = 288) 
Lixi 
(n = 145) 
Clinically important hypoglycaemia
†
 
Patients with events, n (%) 38 (8.1) 32 (6.9) 4 (1.7) 6 (12.0) 1 (1.8) 1 (3.4) 24 (8.2) 24 (8.3) 3 (2.1) 
Events per patient per year, n 0.24 0.14 0.06 0.43 0.07 0.13 0.23 0.17 0.07 
Gastrointestinal disorders 
Gastrointestinal disorders, overall 102 (21.7) 59 (12.6) 86 (36.9) 14 (28.0) 8 (14.5) 14 (48.3) 64 (22.0) 36 (12.5) 54 (37.2) 
Nausea 45 (9.6) 17 (3.6) 56 (24.0) 6 (12.0) 4 (7.3) 10 (34.5) 31 (10.7) 12 (4.2) 37 (25.5) 
Discontinuation due to nausea 2 (0.4) 0 6 (2.6) 1 (2.0) 0 0 1 (0.3) 0 5 (3.4) 
Vomiting 15 (3.2) 7 (1.5) 15 (6.4) 0 0 1 (3.4) 13 (4.5) 5 (1.7) 7 (4.8) 
Discontinuation due to vomiting 2 (0.4) 0 4 (1.7) 0 0 0 2 (0.7) 0 3 (2.1) 
Diarrhoea 42 (9.0) 20 (4.3) 21 (9.0) 8 (16.0) 1 (1.8) 3 (10.3) 26 (8.9) 13 (4.5) 12 (8.3) 
Discontinuation due to diarrhoea 1 (0.2) 0 2 (0.9) 0 0 1 (3.4) 0 0 1 (0.7) 
Abbreviations: HbA1c, glycated haemoglobin; iGlar, insulin glargine 100 U; iGlarLixi, insulin glargine and lixisenatide; Lixi, lixisenatide; OAD, oral 
antihyperglycaemic drug. 
Patient-years of exposure was calculated as time from the first to the last injection of study drug plus 1 day. Number of events per patient-year was 
calculated as number of events divided by total patient-years of exposure.  
†Clinically important hypoglycaemia: symptoms typical of hypoglycaemia accompanied by plasma glucose <54 mg/dL. 
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